- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Relapsed Acute Myeloid Leukemia Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Relapsed Acute Myeloid Leukemia Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Relapsed Acute Myeloid Leukemia Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Relapsed Acute Myeloid Leukemia Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
aNK Program
AT-9283
BI-836858
Binimetinib
BL-8040
Others
Market segment by Application can be divided into
Clinic
Hospital
Others
The key market players for global Relapsed Acute Myeloid Leukemia Drug market are listed below:
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
Amgen Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
BioLineRx, Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celgene Corporation
Cornerstone Pharmaceuticals, Inc.
CTI BioPharma Corp.
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Relapsed Acute Myeloid Leukemia Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Relapsed Acute Myeloid Leukemia Drug, with price, sales, revenue and global market share of Relapsed Acute Myeloid Leukemia Drug from 2019 to 2021.
Chapter 3, the Relapsed Acute Myeloid Leukemia Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Relapsed Acute Myeloid Leukemia Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Relapsed Acute Myeloid Leukemia Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Relapsed Acute Myeloid Leukemia Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Relapsed Acute Myeloid Leukemia Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Relapsed Acute Myeloid Leukemia Drug Market Size & Forecast
1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Value (2016-2026))
1.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume (2016-2026)
1.4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity Analysis
1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Total Production Capacity (2016-2026)
1.5.2 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Relapsed Acute Myeloid Leukemia Drug Market Drivers
1.6.2 Relapsed Acute Myeloid Leukemia Drug Market Restraints
1.6.3 Relapsed Acute Myeloid Leukemia Drug Trends Analysis
2 Manufacturers Profiles
2.1 4SC AG
2.1.1 4SC AG Details
2.1.2 4SC AG Major Business
2.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Product and Services
2.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 AbbVie Inc.
2.2.1 AbbVie Inc. Details
2.2.2 AbbVie Inc. Major Business
2.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Actinium Pharmaceuticals, Inc.
2.3.1 Actinium Pharmaceuticals, Inc. Details
2.3.2 Actinium Pharmaceuticals, Inc. Major Business
2.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Agios Pharmaceuticals, Inc.
2.4.1 Agios Pharmaceuticals, Inc. Details
2.4.2 Agios Pharmaceuticals, Inc. Major Business
2.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Amgen Inc.
2.5.1 Amgen Inc. Details
2.5.2 Amgen Inc. Major Business
2.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Arog Pharmaceuticals, Inc.
2.6.1 Arog Pharmaceuticals, Inc. Details
2.6.2 Arog Pharmaceuticals, Inc. Major Business
2.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Array BioPharma Inc.
2.7.1 Array BioPharma Inc. Details
2.7.2 Array BioPharma Inc. Major Business
2.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Astellas Pharma Inc.
2.8.1 Astellas Pharma Inc. Details
2.8.2 Astellas Pharma Inc. Major Business
2.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Astex Pharmaceuticals, Inc.
2.9.1 Astex Pharmaceuticals, Inc. Details
2.9.2 Astex Pharmaceuticals, Inc. Major Business
2.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 AstraZeneca Plc
2.10.1 AstraZeneca Plc Details
2.10.2 AstraZeneca Plc Major Business
2.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product and Services
2.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 AVEO Pharmaceuticals, Inc.
2.11.1 AVEO Pharmaceuticals, Inc. Details
2.11.2 AVEO Pharmaceuticals, Inc. Major Business
2.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 BioLineRx, Ltd.
2.12.1 BioLineRx, Ltd. Details
2.12.2 BioLineRx, Ltd. Major Business
2.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Boehringer Ingelheim GmbH
2.13.1 Boehringer Ingelheim GmbH Details
2.13.2 Boehringer Ingelheim GmbH Major Business
2.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product and Services
2.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Boston Biomedical, Inc.
2.14.1 Boston Biomedical, Inc. Details
2.14.2 Boston Biomedical, Inc. Major Business
2.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 Bristol-Myers Squibb Company
2.15.1 Bristol-Myers Squibb Company Details
2.15.2 Bristol-Myers Squibb Company Major Business
2.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product and Services
2.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.16 Calithera Biosciences, Inc.
2.16.1 Calithera Biosciences, Inc. Details
2.16.2 Calithera Biosciences, Inc. Major Business
2.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.17 Celgene Corporation
2.17.1 Celgene Corporation Details
2.17.2 Celgene Corporation Major Business
2.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product and Services
2.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.18 Cornerstone Pharmaceuticals, Inc.
2.18.1 Cornerstone Pharmaceuticals, Inc. Details
2.18.2 Cornerstone Pharmaceuticals, Inc. Major Business
2.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.19 CTI BioPharma Corp.
2.19.1 CTI BioPharma Corp. Details
2.19.2 CTI BioPharma Corp. Major Business
2.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product and Services
2.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturer
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Relapsed Acute Myeloid Leukemia Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Relapsed Acute Myeloid Leukemia Drug Manufacturer Market Share
3.4.2 Top 6 Relapsed Acute Myeloid Leukemia Drug Manufacturer Market Share
3.5 Global Relapsed Acute Myeloid Leukemia Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Relapsed Acute Myeloid Leukemia Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2016-2026)
4.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026)
4.3 Europe Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026)
4.4 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026)
4.5 South America Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026)
4.6 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Type (2016-2026)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2016-2026)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Application (2016-2026)
6.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2016-2026)
6.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2026)
7.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2026)
7.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
7.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2026)
8.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2026)
8.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
8.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Region
9.3.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2026)
10.2 South America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2026)
10.3 South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
10.3.1 South America Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country
11.3.1 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Relapsed Acute Myeloid Leukemia Drug Typical Distributors
12.3 Relapsed Acute Myeloid Leukemia Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application, (USD Million), 2021-2026
Table 3. 4SC AG Basic Information, Manufacturing Base and Competitors
Table 4. 4SC AG Major Business
Table 5. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 6. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 8. AbbVie Inc. Major Business
Table 9. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 10. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Actinium Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 12. Actinium Pharmaceuticals, Inc. Major Business
Table 13. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 14. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Agios Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 16. Agios Pharmaceuticals, Inc. Major Business
Table 17. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 18. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Amgen Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Amgen Inc. Major Business
Table 21. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 22. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Arog Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Arog Pharmaceuticals, Inc. Major Business
Table 25. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 26. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Array BioPharma Inc. Basic Information, Manufacturing Base and Competitors
Table 28. Array BioPharma Inc. Major Business
Table 29. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 30. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 32. Astellas Pharma Inc. Major Business
Table 33. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 34. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Astex Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 36. Astex Pharmaceuticals, Inc. Major Business
Table 37. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 38. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. AstraZeneca Plc Basic Information, Manufacturing Base and Competitors
Table 40. AstraZeneca Plc Major Business
Table 41. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 42. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. AVEO Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 44. AVEO Pharmaceuticals, Inc. Major Business
Table 45. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 46. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. BioLineRx, Ltd. Basic Information, Manufacturing Base and Competitors
Table 48. BioLineRx, Ltd. Major Business
Table 49. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 50. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 52. Boehringer Ingelheim GmbH Major Business
Table 53. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 54. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Boston Biomedical, Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Boston Biomedical, Inc. Major Business
Table 57. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 58. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 60. Bristol-Myers Squibb Company Major Business
Table 61. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 62. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. Calithera Biosciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Calithera Biosciences, Inc. Major Business
Table 65. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 66. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 67. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 68. Celgene Corporation Major Business
Table 69. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 70. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 71. Cornerstone Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 72. Cornerstone Pharmaceuticals, Inc. Major Business
Table 73. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 74. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 75. CTI BioPharma Corp. Basic Information, Manufacturing Base and Competitors
Table 76. CTI BioPharma Corp. Major Business
Table 77. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 78. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 79. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 80. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 81. Market Position of Manufacturers in Relapsed Acute Myeloid Leukemia Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 82. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 83. Head Office and Relapsed Acute Myeloid Leukemia Drug Production Site of Key Manufacturer
Table 84. Relapsed Acute Myeloid Leukemia Drug New Entrant and Capacity Expansion Plans
Table 85. Relapsed Acute Myeloid Leukemia Drug Mergers & Acquisitions in the Past Five Years
Table 86. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2016-2021e) & (K Pcs)
Table 87. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Pcs)
Table 88. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2016-2021e) & (USD Million)
Table 89. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026) & (USD Million)
Table 90. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 91. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 92. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2016-2021e) & (USD Million)
Table 93. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (USD Million)
Table 94. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 95. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2026) & (USD/Pcs)
Table 96. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 97. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 98. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2016-2021e) & (USD Million)
Table 99. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (USD Million)
Table 100. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 101. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2026) & (USD/Pcs)
Table 102. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2016-2021e) & (K Pcs)
Table 103. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Pcs)
Table 104. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2021e) & (USD Million)
Table 105. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (USD Million)
Table 106. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 107. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 108. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 109. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 110. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2016-2021e) & (K Pcs)
Table 111. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Pcs)
Table 112. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2021e) & (USD Million)
Table 113. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (USD Million)
Table 114. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 115. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 116. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 117. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 118. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2016-2021e) & (K Pcs)
Table 119. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Pcs)
Table 120. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2016-2021e) & (USD Million)
Table 121. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026) & (USD Million)
Table 122. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 123. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 124. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 125. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 126. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2016-2021e) & (K Pcs)
Table 127. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Pcs)
Table 128. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2021e) & (USD Million)
Table 129. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (USD Million)
Table 130. South America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 131. South America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 132. South America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 133. South America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 134. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2016-2021e) & (K Pcs)
Table 135. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Pcs)
Table 136. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2016-2021e) & (USD Million)
Table 137. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (USD Million)
Table 138. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2016-2021e) & (K Pcs)
Table 139. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Pcs)
Table 140. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2016-2021e) & (K Pcs)
Table 141. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Pcs)
Table 142. Direct Channel Pros & Cons
Table 143. Indirect Channel Pros & Cons
Table 144. Relapsed Acute Myeloid Leukemia Drug Typical Distributors
Table 145. Relapsed Acute Myeloid Leukemia Drug Typical Customers
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Picture
Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type in 2020
Figure 3. aNK Program
Figure 4. AT-9283
Figure 5. BI-836858
Figure 6. Binimetinib
Figure 7. BL-8040
Figure 8. Others
Figure 9. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application in 2020
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Global Relapsed Acute Myeloid Leukemia Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Relapsed Acute Myeloid Leukemia Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales (2016-2026) & (K Pcs)
Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Relapsed Acute Myeloid Leukemia Drug Market Drivers
Figure 20. Relapsed Acute Myeloid Leukemia Drug Market Restraints
Figure 21. Relapsed Acute Myeloid Leukemia Drug Market Trends
Figure 22. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturer in 2020
Figure 23. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturer in 2020
Figure 24. Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Relapsed Acute Myeloid Leukemia Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Relapsed Acute Myeloid Leukemia Drug Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2016-2026)
Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2016-2026)
Figure 29. North America Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026) & (USD Million)
Figure 30. Europe Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026) & (USD Million)
Figure 32. South America Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue (2016-2026) & (USD Million)
Figure 34. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2016-2026)
Figure 35. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2016-2026)
Figure 36. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 38. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2016-2026)
Figure 39. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2016-2026)
Figure 41. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 42. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2016-2026)
Figure 43. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2016-2026)
Figure 44. United States Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2016-2026)
Figure 48. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 49. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2016-2026)
Figure 50. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2016-2026)
Figure 51. Germany Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2016-2026)
Figure 60. China Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2016-2026)
Figure 67. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 68. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2016-2026)
Figure 69. South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
